Citi Reiterates Neutral Rating on Arrowhead Pharma (ARWR)

Go back to Citi Reiterates Neutral Rating on Arrowhead Pharma (ARWR)

Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome

June 3, 2024 7:30 AM EDT

- Plozasiran achieved statistically significant median reductions in triglycerides up to 80% and mean reductions in APOC3 up to 94% at month 10

- Plozasiran achieved a statistically significant reduction in incidence of acute pancreatitis versus placebo

- Plozasiran is the companys first investigational RNAi-based therapy to show clinical efficacy in a Phase 3 study

- Arrowhead plans to highlight recent data for its cardiometabolic pipeline at its June 25, 2024, Cardiometabolic event as part of... More

Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences

May 31, 2024 7:30 AM EDT

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

16th European Glaucoma Society (EGS) Congress June 1-4, 2024

Title: Development and Characterization of Trabecular Meshwork Targeted RNAi Molecule Platform via Intracameral Administration for Glaucoma
Date/Time: June 2, 2024, 10:30 a.m. IST
Session: Poster Section

Jefferies Global Healthcare Conference June 5-6, 2024

Type: Fireside Chat Presentation
Date/Time: June 5, 2024, 12:30 p.m. EDT

European Association for the Study of the Liver (EASL) Congress 2024 June 5-8,... More